Analysis of Schwazze’s Deal Terminations

My article analyzing how tight capital markets and a changing regulatory outlook are derailing the Schwazze deals can be found here, as published in Marijuana Business Daily.

My prior writings on Schwazze (SHWZ), formerly known as Medicine Man Technologies (MDCL) include:

Original Investment Thesis from October 2019 at MJBizDaily’s Investor Intelligence.

First interview with new CEO Justin Dye and review of the management team at MJBizCon in December 2019, published in MJBizDaily’s Investor Intelligence.

Follow-up analysis analyzing the $144 million pro forma revenue target after eliminated pro forma intracompany revenue (which totaled $170 million) following vertical integration at MJBizDaily’s Investor Intelligence.


Leave a Reply